

Verzeichnis der Publikationen

PD Dr. med. Marcus-Willy Agelink
Stand 01.06.2017

ORIGINALIEN IM „PEER-REVIEW“ VERFAHREN

- 1 Malessa R, **Agelink MW**, Diener HC. Dysfunction of visual pathways in HIV-1 Infection. *J Neurol Sci* 1995, 130: 82-87.
- 2 Malessa R, **Agelink MW**, van Schayck R, Mertins L, Brockmeyer NH. Elektrodermale Reflexaktivität und 30:15 Ratio bei HIV-1 Infektion. *Akt Neurol* 1995, 22: 131-135.
- 3 Dammers S, Zeit T, Leonhardt M, Schär V, **Agelink MW**. Malignes neuroleptisches Syndrom. *Dtsch med Wschr* 1995, 120: 1739-1742.
- 4 Malessa R, **Agelink MW**, Himmelmann M, Kloss T, Mertins L, Brockmeyer NH. Nerve conduction changes in asymptomatic HIV-1 seropositive individuals in the absence of other risk factors for neuropathy. *Electromyogr Clin Neurophysiol* 1996, 36: 3-8.
- 5 **Agelink MW**, Dammers S, Zeit T. Clonidin- Abususrisiko bei psychisch kranken Patienten? *Nervenarzt* 1996, 67: 253-255.
- 6 Malessa R, Ohrmann P, **Agelink MW**, Brockmeyer NH, Diener HC. HIV-1-assoziierte autonome Dysfunktion (HIVAD). *Nervenarzt* 1996, 67: 147-154.
- 7 Malessa R, **Agelink MW**, Hengge U, Mertins L, Gastpar M, Brockmeyer NH. Oligosymptomatic neurosyphilis with false negative CSF-VDRL in HIV-infected individuals? *Eur J Med Res* 1996, 1: 299-302.
- 8 **Agelink MW**, Zitzelsberger A, Klieser E. Withdrawal syndrome after discontinuation of venlafaxine. *Am J Psychiatry* 1997, 154: 1473-1474.
- 9 **Agelink MW**, Dammers S, Malessa R, Leonhardt M, Zitzelsberger A, Ullrich H, Zeit T. Nutzen und Risiken der Elektrokrampfbehandlung bei älteren Patienten mit kardiovaskulären Risikofaktoren. *Nervenarzt* 1998, 69: 70-75.
- 10 **Agelink MW**, Dirkes-Kersting A, Zeit T, Bertling R, Malessa R, Klieser E. Sensitivity of carbohydrate deficient transferrin (CDT) in relation to age and duration of abstinence. *Alcohol & Alcoholism* 1998, 33: 164-167.
- 11 **Agelink MW**, Malessa R, Kamcili E, Zeit T, Lemmer W, Bertling R, Klieser E. Cardiovascular autonomic reactivity in schizophrenics under neuroleptic treatment: A potential predictor of short term outcome? *Neuropsychobiology* 1998, 38: 19-24.
- 12 **Agelink MW**, Malessa R, Weisser U, Lemmer W, Zeit T, Majewski T, Klieser E. Alcoholism, peripheral neuropathy (PNP) and cardiovascular autonomic neuropathy (CAN). *J Neurol Sci* 1998, 161: 135-142.

- 13 **Agelink MW**, Malessa R, Lemmer W, Zeit T, Majewski T, Klieser E. Improved autonomic neurocardial balance in short term abstinent alcoholics treated with acamprosate. *Alcohol & Alcoholism* 1998, 33: 602-605.
- 14 **Agelink MW**, Zeit T, Klieser E. Prolonged bradycardia complicated combined venlafaxine and electroconvulsive therapy. *Br J Psychiatry* 1998, 173: 441.
- 15 **Agelink MW**, Ullrich H, Lemmer W, Dirkes-Kersting A, Zeit T. Screening for concomitant alcohol abuse in schizophrenia: Clinical significance of the Munich Alcoholism Test and laboratory parameters. *Eur Addict Res* 1999, 5: 82-87.
- 16* Wurthmann C, Gregor J, **Agelink MW**, Effenberger O, Baumann B, Döhring W, Bogerts B. Morphometrische Untersuchung der Hirnmorphologie bei Agoraphobien. *Psycho* 2000, 26: 451-454.
- 17 Postert T, Lack B, Kuhn W, Jergas M, Andrich J, Braun B, Przuntek H, Sprengelmeyer R, **Agelink MW**, Büttner T. Basal ganglia alterations and brain atrophy in Huntington`s disease depicted by transcranial real time sonography. *J Neurol Neurosurg Psychiatry* 1999, 67: 457-462.
- 18 **Agelink MW**, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T, Klieser E. Effects of newer atypical antipsychotics on autonomic neurocardiac function: A comparison between amisulpride, olanzapine, sertindole and clozapine. *J Clin Psychopharmacol* 2001, 21: 8-13.
- 19 **Agelink MW**, Majewski T, Wurthmann C, Postert T, Linka T, Rotterdam S, Klieser E. Autonomic neurocardiac function in patients with major depression and effects of antidepressive treatment with nefazodone. *J Affect Dis* 2001, 62: 187-198.
- 20 Eich H, **Agelink MW**, Lemmer W, Lehmann E, Klieser E. Akupunktur bei leichten bis mittelschweren depressiven Episoden und Angststörungen: Ergebnisse einer experimentiellen Untersuchung. *Fortschr Neurol Psychiat* 2000, 68: 137-144.
- 21* **Agelink MW**, Zeit T, Baumann B, Majewski T, Lemmer W, Postert T, Lukas K, Klieser E. In vivo cardiovascular effects of the new atypical neuroleptic sertindole. *Int J Psychiatry Clin Pract* 2001, 5: 33-40.
- 22 **Agelink MW**, Malessa R, Baumann B, Majewski T, Akila F, Zeit T, Ziegler D. Standardized tests of heart rate variability (HRV): Normal ranges obtained from 309 healthy humans and effects of age, gender and heart rate. *Clin Autonom Res* 2001; 11:99-108.
- 23 **Agelink MW**, Majewski T, Andrich J, Mück-Weymann M. Short term effects of intravenous benzodiazepines on autonomic neurocardiac regulation in man. A comparison between midazolam, diazepam and lorazepam. *Crit Care Med* 2002; 30: 997-1006.

- 24 **Agelink MW**, Andrich J, Postert T, Würzinger U, Zeit T, Klotz P, Przuntek H. Relationship between electroconvulsive therapy (ECT), cognitive side effects, neuron-specific enolase and protein S-100. *J Neurol Neurosurg & Psychiatry* 2001; 71:394-396.
- 25 **Agelink MW**, Brockmeyer N, Ullrich H. Sildenafil does not influence autonomic neurocardiac control assessed by standard measurements of heart rate variability *Circulation* 2001; 104: pE145.
- 26 **Agelink MW**, Ullrich H, Baumann B, Strum S, Majewski T. Effects of reboxetine, a selective norepinephrine re-uptake inhibitor, on sympathetic and parasympathetic outflow to the heart. *Psychopharmacology* 2002; 163: 151-156.
- 27 Andrich J, Schmitz T, Saft, C, Bingöl HR, Kraus P, Epplen JT, Przuntek H, **Agelink MW**. Autonomic nervous system function in Huntington Disease. *J Neurol Neurosurg & Psychiatry* 2002; 72: 726-731.
- 28 Mück-Weymann M, Acker J, **Agelink MW**. Autonomic responses of blood vessels and sweat glands in patients with schizophrenia treated with olanzapine or clozapine. *Psychopharmacology* 2001; 157: 368-372.
- 29 **Agelink MW**, Schmitz T, Rembrink K, Beckerling D, Mück-Weymann M, Brockmeyer NH. Cardiovascular effects of sildenafil citrate (VIAGRA®): A naturalistic cross-over study. *Eur J Med Res* 2001; 6: 459-464.
- 30 Baumann B, Bielau H, Krell D, **Agelink MW**, Diekmann S, Wurthmann C, Trübner K, Bernstein HG, Danos P, Bogerts B. (mit Unterstützung der Deutschen Forschungsgemeinschaft - DFG 799/6-1 - und dem Ministerium für Bildung und Forschung - BMBF 01 ZZ 9510-). Circumscribed numerical deficit of dorsal raphe neurons in mood disorders. *Psychol Med* 2002; 32: 93-103.
- 31 **Agelink MW**, Boz C, Ullrich H, Andrich J. Relationship between major depression and heart rate variability. Clinical consequences and implications for antidepressive treatment. *Psychiatry Res* 2002; 113: 139-149
- 32 **Agelink MW**. Prolongation of QTc interval and antipsychotics. *Am J Psychiatry* 2002; 159:1063.
- 33 **Agelink MW**, Ullrich H, Passenberg P, Sayar K, Brockmeyer NH. Superior safety of reboxetine over amitryptiline in the elderly: a case report. *Eur J Med Res* 2002; 7: 415-416.
- 34* Mück-Weymann M, Moesler T, Joraschky P, Rebensburg M, **Agelink MW**. Depression modulates autonomic cardiac control: a physio-psychological pathway linking depression and mortality. *German J Psychiatry* 2002; 5: 67-69.

- 35 **Agelink MW**, Sanner D, Eich H, Pach J, Bertling R, Lemmer W, Klieser E, Lehmann E. Beeinflußt Akupunktur die autonom kardiale Regulation bei Patienten mit leichten depressiven Episoden oder Angststörungen? *Fortschr Neurol Psychiatr*; 2003; 71: 141-149.
- 36 **Agelink MW**, Sayar K, Klieser E. Usefulness of heart rate variability (HRV) for monitoring clozapine plasma levels. *Pharmacopsychiatry* 2003; 36: 166-167.
- 37 Kavuk I, Yavuz A, Cetindere Ü, **Agelink MW**, Diener HC. Epidemiology of chronic daily headache. *Eur J Med Res* 2003; 8: 236-240
- 38 Ullrich H, Passenberg P. **Agelink MW**. Depressive Störung mit Suizidversuch nach Einnahme von Valsartan-Hydrochlorothiazid. *Deutsch Med Wochenschr (DMW)* 2003; 128: 2534-2536
- 39 Loeffler S, Fehsel K, Henning U, Fischer J, **Agelink MW**, Kolb-Bachofen V, Klimke A. Increased apoptosis of neutrophils in a case of clozapine-induced agranulocytosis. *Pharmacopsychiatry* 2003; 36: 37-41.
- 40 Kavuk I, **Agelink MW**, Gaertner T, Kastrup O, Doerfler A, Maschke M, Diener HC. Wernicke`s encephalopathy: unusual contrast enhancement revealed by magnetic resonance imaging. *Eur J Med Res* 2003; 8: 492-494
- 41* Kämpf P, **Agelink MW**, Maß R, Jahn H, Schäfer I, Naber D. Amisulpride in addition to clozapine: a retrospective study indicates improved efficacy and good tolerability. *German J Psychiatry* 2003; 6: 64-68
- 42 **Agelink MW**, Baumann B, Sanner D, Kavuk I, Mück-Weymann M. Komorbidität zwischen kardiovaskulären Erkrankungen und Depressionen. *Deutsch Med Wochenschr (DMW)* 2004; 129: 697-700
- 43 Kavuk I, Katsarava Z, Stang A, **Agelink MW**, Limmroth V, Diener HC. Neues zur Epidemiologie von Kopfschmerzen. *Fortschr Neurol Psychiatr* 2004; 72: 184-191
- 44 **Agelink MW**, Klimke A, Cordes J, Sanner D, Kavuk I, Malessa R, Klieser E, Baumann B. A functional-structural model to understand cardiac autonomic nervous system (ANS) dysregulation in affective illness and to elucidate the ANS effects of antidepressive treatment. *Eur J Med Res* 2004; 9: 37-50
- 45* **Agelink MW**, Baumann B, Sanner D, Kavuk I, Mück-Weymann M. Komorbidität zwischen kardiovaskulären Erkrankungen und Depressionen. *PsychoNeuro* 2004; 30: 541-547
- 46 Andrich J, Saft C, Arz A, Schneider B, **Agelink MW**, Kraus PH, Kuhn W, Muller T. Hyperhomocysteinaemia in treated patients with Huntington`s disease. *Mov Disord* 2004; 19: 226-228
- 47 Kavuk I, Koeppen S, **Agelink MW**, Doerfler A, Limmroth V, Diener HC. Transient MRI abnormalities associated with partial status epilepticus. *J Neurol* 2004; 251: 1156-1157

- 48 Kavuk I, Yavuz A, Cetindere U, **Agelink MW**, Diener HC. Chronic headache: a focus on medication overuse. *Eur J Med Res* 2004; 9: 285

Nach Einreichen der Habilitationsschrift

- 50 **Agelink MW**, Kavuk I, Ak I. Clozapine combined with amisulpride for refractory schizophrenia: a retrospective analysis of 7 cases. *Am J Psychiatry* 2004; 924-925
- 51 Cordes J, Streit M, Loeffler S, Wilmsdorff M, **Agelink MW**, Klimke A. Reversible neutropenia during treatment with olanzapine: three case reports. *World J Biol Psychiatry* 2004; 5: 230-234
- 52 Selekler HM, Kavuk I, **Agelink MW**, Komsuoglu S. Questioning aggravation of headache during migraine attacks. *Eur J Med Res* 2004; 9: 279-281
- 53 Kavuk I, Katsarava Z, Selekler M, Sayar K, **Agelink MW**, Limmroth V, Diener HC. Clinical features and therapy of medication overuse headache. *Eur J Med Res* 2004; 9: 565-569
- 54 Kämpf P, **Agelink MW**, Naber D. Augmentation of clozapine with amisulpride. *Pharmacopsychiatry* 2005; 38: 39-40
- 55 Cordes J, Mobascher A, Arends M, **Agelink MW**, Klimke A. Ein neues Behandlungsverfahren der Depression: Die repetitive transkranielle Magnetstimulation (rTMS). *Deutsch Med Wochenschr* 2005; 130: 889-892
- 56 Biela H, Mawrin C, Krell D, **Agelink MW**, Truebner K, Davis R, Gos T, Bogerts B, Bernstein HG, Baumann B. Differences in activation of the dorsal raphe nucleus depending on performance of suicide. *Brain Res* 2005; 1039: 43-52
- 57 Kavuk I, Hufnagel A, **Agelink MW**, Limmroth V, Dörfler A, Sayar K, Selekler M, Diener HC, Koeppen S. MRI changes with associated with partial status epilepticus. *Eur J Med Res* 2005; 10: 243-246
- 58 Mobascher J, Zielasek J, Schuier FJ, Mobascher A, Grohmann R, **Agelink MW**, Cordes J. Guillan-Barre-syndrome after septicemia following clozapine-induced agranulocytosis. *Pharmacopsychiatry* 2005; 38: 329-330
- 59 Biela H, Truebner K, Krell D, **Agelink MW**, Bernstein HG, Stauch R, Mawrin C, Danos P, Gerhard L, Bogerts B, Baumann B. Volume deficits of subcortical nuclei in mood disorders: a post mortem study. *Eur Arch Psychiatry Clin Neurosci* 2005; 255: 401-412.
- 60* Siepmann M, Joraschky P, Rebensburg M, Rittger H, Mösler T, **Agelink MW**, Mück-Weymann M. Ist die autonome kardiale Regulation bei Patienten mit Depression und koronarer Herzerkrankung gestört? *Zeitschr Klin Psychol Psychother* 2005;34:277-281
- 61* Blaschke S, Kornischka J, **Agelink MW**. Deutliche Gewichtsreduktion nach Aripiprazol. *Nervenheilkunde* 2005; 24: 426-427

- 62 Fehsel K, Loeffler S, Krieger K, Henning U, **Agelink MW**, Kolb-Bachofen V, Klimke A. Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. *J Clin Psychopharmacol* 2005; 25: 419-426
- 63* Cordes J, Klimke A, Kornischka J, **Agelink MW**, Hauner H. Therapie der Schizophrenie mit Antipsychotika: Gewichtszunahme ist ein relevanter Faktor. *Der Neurologe & Psychiater (DNP)* 2006; 1-2: 45-51.
- 64 Cordes J, Arends M, Mobascher A, Brinkmeyer J, Kornischka J, Eichhammer P, Klimke A, Winterer G, **Agelink MW**. Potential clinical targets of repetitive transcranial magnetic stimulation treatment in schizophrenia. *Neuropsychobiology* 2006; 54: 87-99
- 65* **Agelink MW**, Kornischka J, Cordes J, Klimke A, Hauner H, Ziegler D. Allgemeinmedizinische Aspekte der Therapie mit Antipsychotika der zweiten Generation. *Deutsches Ärzteblatt* 2006; 2437-2443
- 66 Kornischka J, Cordes J, **Agelink MW**. 40 Jahre Beta-Blocker in der Psychiatrie: Eine systematische Übersicht. *Fortschr Neurol Psychiatr* 2007; 75: 199-210
- 67 Kornischka J, Assion HJ, Machleidt K, **Agelink MW**. Psychische und psychosoziale Probleme bei Spätaussiedlern. *Psychiatr Prax* 2008; 35: 60-66.
- 68 Baer J, Wernich K, Boettger S, Cordes J, Boettger MK, Loeffler S, Kornischka J, **Agelink MW**. Relationship between cardiovagal modulation and psychotic state in patients with schizophrenia. *Psychiatry Res* 2008; 157: 255-257.
- 69 Luckhaus, C, Hennersdorf M, Bell M, **Agelink MW**, Zielasek J, Cordes J. Brugada-syndrom as a potential cardiac risk factor during electroconvulsive therapy. *World J Biol Psychiatry* 2008; 9: 150-153.
- 70 Stirban A, Laude D, Elghozi JL, Sander D, **Agelink MW**, Hilz MJ, Ziegler D. Acute effects of sildanefil on flow mediated dilatation and cardiovascular autonomic nerve function in type-2 diabetic patients. *Diabetes Metab Res Rev* 2009; 25: 136-143.
- 71 Siepmann M, Rauh R, Dill O, **Agelink MW**, Mück-Weymann M. The effects of sildenafil on heart rate variability in healthy subjects. *J Cardiovasc Pharmacol* 2007; 50: 598-600.
- 72 Baer KJ, Boettger MK, Andrich J, Epplen JT, Fischer F, Cordes J, Koschke M, **Agelink MW**. Cardiovagal modulation upon postural change is altered in Huntington´s disease. *J Neurol Neurosurg and Psychiatry* 2008; 15: 869-871.
- 73 Baer KJ, Boettger MK, Schulz S, Harzendorf C, **Agelink MW**, Yeragani VK, Chokka P, Voss A. The interaction between pupil function and cardiovascular regulation in patients with acute schizophrenia. *Clin Neurophysiol* 2008; 119: 2209-2213.
- 74 Boettger MK, Baer KJ, Dohrmann A, Müller H, Mertins L, Brockmeyer NH, **Agelink MW**. Increased vagal modulation in atopic dermatitis. *J Dermatol Sci* 2009; 53: 55-59.

- 75 Cordes J, Sinha-Röder A, Kahl KG, Malevani J, Thuenker J, Lange-Asschenfeldt C, Hauner H, **Agelink MW**, Klimke A. Therapeutische Optionen für ein Gewichtsmanagementprogramm bei mit atypischen Antipsychotika behandelten schizophrenen Patienten. *Fortschr Neurol Psychiatr* 2008; 76: 703-714.
- 76 Mobascher A, Arends M, Eschweiler GW, Brinkmeyer J, **Agelink MW**, Kornischka J, Winterer G, Cordes J. Biological correlates of prefrontal activating and temporoparietal inhibiting treatment with repetitive transcranial magnetic stimulation (rTMS). *Fortschr Neurol Psychiatr* 2009; 77; 432-443.
- 77 Mittrach M, Thünker J, Winterer G, **Agelink MW**, Regenbrecht G, Arends M, Mobascher A, Kim SJ, Wölwer W, Brinkmeyer J, Gaebel W, Cordes J. The tolerability of rTMS treatment in schizophrenia with respect to cognitive function. *Pharmacopsychiatry* 2010; 43: 110-117.
- 78 Baer KJ, Ebert A, Boettger MK, Merz S, Kiehnopf M, Jochum T, Juckel G, **Agelink MW**. Is successful electroconvulsive therapy (ECT) related to stimulation of the vagal system? *J Affect Disord* 2010; 125: 323-329.
- 79 Cordes J, Thünker J, **Agelink MW**, Arends M, Mobascher A, Wobrock T, Schneider-Axmann T, Brinkmeyer J, Mittrach M, Regenbrecht G, Wölwer W, Winterer G, Gaebel W. Effects of 10Hz repetitive transcranial magnetic stimulation (rTMS) on clinical global impression in chronic schizophrenia. *Psychiatr Res* 2010; 177: 32-36.
- 80 Cordes J, Kahl KG, Werner C, Henning U, Regenbrecht G, Larisch R, Schmid-Kraepelin C, Thünker J, **Agelink MW**, Löffeler S, Hohlfeld T, Gaebel W, Klimke A. Clomipramine-induced serum prolactin as a marker for serotonin and dopamine turnover: results of an open label study. *Eur Arch Psychiatry Clin Neurosci* 2011; 261: 567-573.
- 81 Cordes J, Thünker J, Regenbrecht G, Zielasek J, Correll CU, Schmidt-Kraepelin C, Lange-Asschenfeldt C, **Agelink MW**, Kahl KG, Gaebel W, Klimke A. Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty four and 48 week results from a 6 month randomized trial. *World J Biol Psychiatry* 2014; 15: 229-241.
- 82 Stein M, Dietrich DE, **Agelink MW**, Becker W, Chrysanthou C, Driessen M, Machleidt W, Reker T, Schneider U, Schulze-Mönking H, Emrich HM, Rothermundt M. Naturalistic pharmacotherapy of acute episodes of schizophrenic disorders in comparison to treatment guidelines. *Pharmacopsychiatry* 2012; 45: 189-195.
- 83 Wölwer W, Lowe A, Brinkmeyer J, Streit M, Habakuck M, **Agelink MW**, Mobascher A, Gaebel W, Cordes J. Repetitive transcranial magnetic stimulation (rTMS) improves facial affect recognition in schizophrenia. *Brain Stimul* 2014; 7: 559-563.
- 84 Spindelegger CJ, Papageorgiou K, Grohmann R, Engel R, Grell W, Konstantinidis A, **Agelink MW**, Bleich S, Ruether E, Toto S, Kasper S. Cardiovascular adverse reactions during antidepressant treatment: A drug surveillance report of German speaking countries between 1993 and 2010. *Int J Neuropsychopharmacol* 2014; Oct31; 18(4). Pii:pyu080.doi:10.1093/ijnp/pyu080.

- 85 Brinkmeyer J, **Agelink MW**, Habakuck M, Mobascher A, Wölwer W, Cordes J. High frequency repetitive transcranial magnetic stimulation (rTMS) reduces EEG hypofrontality in patients with schizophrenia. *Psychiatry Res* 2016;236:199:201.
- 86 Harenbrock S., **Agelink MW**, Effect Depends on Subjective Perception, *Dtsch Arztebl. Int.* 2017; 114(3): 43-44.